US EditionStem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin
UNITED STATES, JUN 20 – Zimislecel therapy restored insulin production and eliminated severe hypoglycemia in all 12 trial patients, with 83% becoming insulin independent after one year, Vertex reported.
- Vertex Pharmaceuticals will hold an investor meeting in Chicago on June 20, 2025, to present encouraging results from their clinical trial of zimislecel in individuals with type 1 diabetes.
- The event follows updated Phase 1/2 FORWARD-101 trial data showing 12 patients received a full zimislecel dose and were followed for over one year.
- All patients achieved ADA HbA1c targets below 7%, over 70% time-in-range, elimination of severe hypoglycemic events, and 10 of 12 became insulin free.
- Michael R. Rickels called it remarkable that all 12 patients with severe hypoglycemia met glycemic control goals, and Bozic said results reinforce zimislecel's transformative potential.
- These findings suggest zimislecel could transform type 1 diabetes treatment, although it remains investigational and not yet approved globally.
72 Articles
72 Articles
Most of a small group of patients who received a cell-based infusion did not need more than insulin, but the medicine may not be suitable for those with type 1 more controlled diabetes A single infusion of a cell-based therapy may have treated 10 out of 12 people with the most serious type of diabetes 1. One year later, these 10 patients no longer need insulin. The other two need much lower doses. The experimental treatment called zimislecell an…
Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes
Clinical studies on the treatment of type 1 diabetes with device-encapsulated pancreatic precursor cells derived from human embryonic stem cells found that insulin output was insufficient for clinical benefit. We are conducting a phase 1/2, open-label, multicenter trial aimed at optimizing cell engraftment (ClinicalTrials.gov identifier: NCT03163511 ). Here we report interim, 1-year outcomes in one study group that received 2–3-fold higher cell …
Coverage Details
Bias Distribution
- 92% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
